

Piers E M Patten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770079/publications.pdf>

Version: 2024-02-01

64
papers

2,883
citations

257101

24
h-index

189595

50
g-index

66
all docs

66
docs citations

66
times ranked

4965
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology</i> , The, 2021, 22, 765-778.	5.1	491
2	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
3	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet</i> , The, 2020, 396, 1885-1894.	6.3	206
4	CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. <i>Blood</i> , 2008, 111, 5173-5181.	0.6	197
5	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
6	A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. <i>Blood</i> , 2011, 117, 5463-5472.	0.6	187
7	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	15.2	182
8	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	7.7	93
9	Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. <i>British Journal of Haematology</i> , 2020, 190, e279-e282.	1.2	89
10	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- κ B Activation and <i>De novo</i> Gene Transcription. <i>Cancer Research</i> , 2010, 70, 7523-7533.	0.4	88
11	Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. <i>British Journal of Haematology</i> , 2011, 154, 216-222.	1.2	69
12	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. <i>British Journal of Haematology</i> , 2019, 185, 656-669.	1.2	53
13	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	0.6	53
14	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012, 120, 4802-4811.	0.6	52
15	Targeting the tumor microenvironment in chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2312-2324.	1.7	41
16	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. <i>British Journal of Cancer</i> , 2021, 125, 939-947.	2.9	41
17	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
18	A national service for delivering CD19 CAR in large B-cell lymphoma – The UK real-world experience. <i>British Journal of Haematology</i> , 2022, 198, 492-502.	1.2	40

#	ARTICLE	IF	CITATIONS
19	Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 321-326.	2.5	37
20	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016, 1, .	2.3	29
21	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 344-359.	1.2	29
22	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1445-1447.	7.7	29
23	The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. <i>Haematologica</i> , 2020, 105, 1593-1603.	1.7	28
24	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016, 128, 563-573.	0.6	27
25	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , 2019, 134, 767-767.	0.6	27
26	Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 642-642.	0.6	26
27	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018, 132, 182-182.	0.6	20
28	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. <i>Blood</i> , 2020, 136, 1-3.	0.6	18
29	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2022, 196, 70-78.	1.2	14
30	Torque Teno Virus 10 Isolated by Genome Amplification Techniques from a Patient with Concomitant Chronic Lymphocytic Leukemia and Polycythemia Vera. <i>Molecular Medicine</i> , 2011, 17, 1338-1348.	1.9	13
31	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. <i>Leukemia</i> , 2021, 35, 3581-3584.	3.3	13
32	Effect of CD3/CD28 Bead-Activated and Expanded T Cells on Leukemic B Cells in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2005, 174, 6562-6563.	0.4	12
33	<sc>ALK</sc>-positive large B-cell lymphoma with strong <sc>CD</sc>30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. <i>Histopathology</i> , 2016, 69, 880-882.	1.6	12
34	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 544-557.	1.2	12
35	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	2.2	11
36	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	0.6	11

#	ARTICLE	IF	CITATIONS
37	Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2022, 196, 864-870.	1.2	10
38	Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7506-7506.	0.8	9
39	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. <i>Leukemia</i> , 2022, 36, 1324-1335.	3.3	9
40	<i>In vitro</i> and <i>in vivo</i> evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, 497-505.	1.7	8
41	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	0.6	8
42	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 2636-2636.	0.6	8
43	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2051-2056.	0.6	7
44	Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e535.	1.2	7
45	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	1.2	7
46	A retrospective analysis of postâ€transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018, 100, 98-103.	1.1	6
47	Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e45-e46.	0.9	5
48	BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes. <i>Haematologica</i> , 2022, 107, 1181-1184.	1.7	5
49	Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells. <i>Blood</i> , 2011, 118, 975-975.	0.6	4
50	Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. <i>Blood</i> , 2012, 120, 2545-2545.	0.6	4
51	Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling. <i>Blood</i> , 2018, 132, 237-237.	0.6	2
52	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
53	Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure. <i>Blood</i> , 2020, 136, 27-28.	0.6	2
54	Lymphoma diagnosis: an update. <i>Clinical Medicine</i> , 2007, 7, 620-624.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Laser capture microscopy as a tool for the assessment of lineage-specific chimaerism from archived blood and bone marrow films. <i>British Journal of Haematology</i> , 2007, 136, 677-678.	1.2	1
56	IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.. <i>Blood</i> , 2006, 108, 2808-2808.	0.6	1
57	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 119-119.	0.6	1
58	Chronic lymphocytic leukaemia. <i>Medicine</i> , 2021, 49, 286-292.	0.2	0
59	In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning.. <i>Blood</i> , 2007, 110, 1196-1196.	0.6	0
60	Detection of Activation-Induced Cytidine Deaminase RNA In CLL Cells Correlates with Shorter Patient Survival and High Numbers of CD38+ Cells. <i>Blood</i> , 2010, 116, 2415-2415.	0.6	0
61	Chronic Lymphocytic Leukemia B Cells Variably Express Functional Activation-Induced Cytosine Deaminase Protein. <i>Blood</i> , 2010, 116, 378-378.	0.6	0
62	Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 316-316.	0.6	0
63	Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation. <i>Blood</i> , 2013, 122, 2583-2583.	0.6	0
64	Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones. <i>Blood</i> , 2021, 138, 3716-3716.	0.6	0